Trial Profile

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonrotoclax (Primary) ; Zanubrutinib (Primary) ; Obinutuzumab; Venetoclax
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Acronyms CELESTIAL; CELESTIAL-TNCLL
Sponsors BeOne Medicines

27 Feb 2025 Status changed from recruiting to active, no longer recruiting, according to BeiGene media release.
10 Dec 2024 Study design presented at the 66th American Society of Hematology Annual Meeting and Exposition
05 Nov 2024 According to a BeiGene media release, early safety and efficacy results from this trial, will be presented, at the 66th ASH Annual Meeting and Exposition in San Diego, Dec 7-10.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com